Studieoverzicht
BOOG nr.: |
Status: ( View all )
|
Indication: ( View all )
|
Subindication: |
Menopausal status: |
2017-02 PERIDENO | Closed | Adjuvant | HER2-, any HR | Postmenopausal | ||||||||||||||
2017-01 NEOLBC | Follow up | Neoadjuvant | HER2- HR+ | Postmenopausal | ||||||||||||||
2016-01 TOP-1 | Follow up | Data registration | HER2- HR+ | Postmenopausal | ||||||||||||||
2015-02 MonaLEEsa-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2015-01 Monarch-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2014-01 MONALEESA-2 | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-06 Biomarker Study Everolimus | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2013-05 BELLE-3 | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2012-01 BALLET | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2011-01 Abiraterone | Follow up | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2009-05 BOLERO 2 | Closed | Advanced/metastatic | HER2- HR+ | Postmenopausal | ||||||||||||||
2006-05 IDEAL | Follow up | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-04b TEAM IIb | Follow up | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-04a TEAM IIa | Closed | Neoadjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2006-02 OMEGA | Closed | Advanced/metastatic | Any HER2, any HR | Postmenopausal | ||||||||||||||
2006-01 DATA | Closed | Adjuvant | Any HER2, HR+ | Postmenopausal | ||||||||||||||
2001-01 TEAM | Closed | Adjuvant | Any HER2, HR+ | Postmenopausal |